CRDMO firm Aragen receives $100 million from Quadria Capital

Contract research, development and manufacturing organisation (CRDMO) Aragen Life Science has secured a $100 million investment from Asia healthcare-focused private equity fund Quadria Capital.

Quadria will acquire a minority stake in Aragen, at an approximate valuation of $1.4 billion, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors, Aragen (formerly GVK Bio) said on Monday.

The funding will support the strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe. Quadria joins Goldman Sachs as the second strategic investor, it said in a release.

“The investment marks a pivotal moment as we scale to meet the needs of a rapidly evolving market,” CEO Manni Kantipudi said. The expanded capabilities will allow the firm to meet the rising demand for integrated discovery and manufacturing services and help customers accelerate programmes to market faster and more efficiently. Aragen has more than 400 global clientele, including 15 of the top 20 large pharma. It operates through a global network of eight sites with a team of around 4,500 employees.

The funding announcement comes ahead of JPM Week 2025, where Aragen said it is expected to secure additional outsourcing partnerships.

“The pharmaceutical outsourcing sector presents compelling growth opportunities, especially in the current environment which is driven by global supply chain reorganisation. Aragen’s impressive track record... look forward to partnering with them and supporting their next phase of growth,” Managing Partner and co-Founder of Quadria Capital Amit Varma said.